Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2, Study to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-vs-Host Disease Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT04014790 is registered in ClinicalTrials.gov with Regimmune Corporation as lead sponsor.

NCT NCT04014790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04014790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2, Study to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-vs-Host Disease Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Regimmune Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 25, 2019
Completion date
April 3, 2023
Enrollment
49 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute-graft-versus-host disease, graft vs host disease, graft-versus-host-disease, prevention of agvhd